Poliomyelitis - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Poliomyelitis - Pipeline Review, H1 2018’, provides an overview of the Poliomyelitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poliomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Poliomyelitis

The report reviews pipeline therapeutics for Poliomyelitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Poliomyelitis therapeutics and enlists all their major and minor projects

The report assesses Poliomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Poliomyelitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Poliomyelitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Poliomyelitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

Biological E Ltd

Biological Mimetics Inc

Boryung Pharmaceutical Co Ltd

GlaxoSmithKline Plc

Grifols SA

Johnson & Johnson ...

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

Biological E Ltd

Biological Mimetics Inc

Boryung Pharmaceutical Co Ltd

GlaxoSmithKline Plc

Grifols SA

Johnson & Johnson

Kaketsuken

LG Chem Ltd

Nanolek

Panacea Biotec Ltd

Sanofi

Sanofi Pasteur SA

Sentinext Therapeutics Sdn Bhd

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Poliomyelitis – Overview

Poliomyelitis – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Poliomyelitis – Overview

Poliomyelitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Poliomyelitis – Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Poliomyelitis – Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech Ltd

Biological E Ltd

Biological Mimetics Inc

Boryung Pharmaceutical Co Ltd

GlaxoSmithKline Plc

Grifols SA

Johnson & Johnson

Kaketsuken

LG Chem Ltd

Nanolek

Panacea Biotec Ltd

Sanofi

Sanofi Pasteur SA

Sentinext Therapeutics Sdn Bhd

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Takeda Pharmaceutical Co Ltd

Poliomyelitis – Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPVGVI-3000 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-2348 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVC – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVD – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio (virus like particle, bivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [serotype 2] vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [serotype 2] vaccine 1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [serotype sabin 1, 3] (bivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [strain Sabin] vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [strain Sabin] vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis [serotype PV3] (virus like particles) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-195 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poliomyelitis – Dormant Projects

Poliomyelitis – Discontinued Products

Poliomyelitis – Product Development Milestones

Featured News & Press Releases

May 21, 2018: A single-injection vaccine for the polio virus

Apr 19, 2018: Sinovac Announces Preliminary Results of Phase III Trial on sIPV

May 16, 2017: Bilthoven Biologicals will produce polio vaccine in Bohumil, Czech Republic

Nov 24, 2016: Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine– Hexaxim

Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine

Mar 03, 2014: Inactivated Polio Vaccines Broadly Available for the World's Children in the Drive Toward Polio Eradication

Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima

Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine

Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Pediatric Vaccine In European Markets

May 11, 2011: Sanofi Pasteur Launches Pentaxim In China

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Poliomyelitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Tables

Number of Products under Development for Poliomyelitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Poliomyelitis – Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018

Poliomyelitis – Pipeline by Bharat Biotech Ltd, H1 2018

Poliomyelitis – Pipeline by Biological E Ltd, H1 2018

Poliomyelitis – Pipeline by Biological Mimetics Inc, H1 2018

Poliomyelitis – Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018

Poliomyelitis – Pipeline by GlaxoSmithKline Plc, H1 2018

Poliomyelitis – Pipeline by Grifols SA, H1 2018

Poliomyelitis – Pipeline by Johnson & Johnson, H1 2018

Poliomyelitis – Pipeline by Kaketsuken, H1 2018

Poliomyelitis – Pipeline by LG Chem Ltd, H1 2018

Poliomyelitis – Pipeline by Nanolek, H1 2018

Poliomyelitis – Pipeline by Panacea Biotec Ltd, H1 2018

Poliomyelitis – Pipeline by Sanofi, H1 2018

Poliomyelitis – Pipeline by Sanofi Pasteur SA, H1 2018

Poliomyelitis – Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2018

Poliomyelitis – Pipeline by Serum Institute of India Ltd, H1 2018

Poliomyelitis – Pipeline by Shantha Biotechnics Pvt Ltd, H1 2018

Poliomyelitis – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Poliomyelitis – Dormant Projects, H1 2018

Poliomyelitis – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Poliomyelitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Figures

Number of Products under Development for Poliomyelitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports